N6-Isopentenyladenosine (iPA) is a member of the cytokinins, a family of plant hormones that regulate plant cell growth and differentiation. iPA is present in mammalian cells in a free form, as a mononucleotide in the cytoplasm, or in a tRNA-bound form. Its antiproliferative activity against cancer cells lines has been reported by several authors. We show that iPA inhibits the growth of human breast cancer MCF-7 cells in a dose-dependent manner with a concentration of 12.2 μM, which causes 50% inhibition of cell viability. The cell cycle analysis by flow cytometry showed that iPA-induced growth arrest could be associated to apoptosis. The interaction of DNA with iPA was studied in aqueous solution at physiological conditions by ultraviolet–vis spectroscopy. A binding constant KiPA–DNA = 4.4 × 103 M−1 was calculated and this value, together with the shift of absorbance, suggests iPA–DNA interaction at DNA surface.
Get full access to this article
View all access options for this article.
References
1.
BagchiS., RaychaudhuriP.2010. Damaged-DNA binding protein-2 drives apoptosis following DNA damage. Cell Div, 5:1–5.
2.
BifulcoM., MalfitanoA.M., ProtoM.C., SantoroA., CarusoM.G., LaezzaC.2008. Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug. Anti Cancer Agents Med Chem, 8:200–204.
3.
ColomboF., FavellaS., De CeccoL., TortoretoM., PratesiG., CiuffredaP., OttriaR., SantanielloE., CicatielloL., WeiszA., DraganiT.A.2009. Pharmacogenomics and analogues of the antitumor agent N6-isopentenyladenosine. Int J Cancer, 124:2179–2185.
4.
DivekarA.Y., SlocumH.K., HakalaM.T.1973. N6-(Δ2-Isopentenyl)adenosine 5'-monophosphate: formation and effect on purine metabolism in cellular and enzymatic systems. Mol Pharm, 10:529–543.
5.
GalloR.C., Whang-PengJ., PerryS.1969. Isopentenyladenosine stimulates and inhibits mitosis of human lymphocytes treated with phytohemagglutinin. Science, 165:400–402.
6.
HendryL.B., MaheshV.B., BransomeE.D., EwingD.E.2007. Small molecule intercalation with double stranded DNA: implications for normal gene regulation and for predicting the biological efficacy and genotoxicity of drugs and other chemicals. Mutat Res, 623:53–71.
7.
IshiiY., HoriY., SakaiS., HonmaY.2002. Control of differentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant redifferentiation-inducing hormones. Cell Growth Differ, 13:19–26.
8.
KastanM.B., BartekJ.2004. Cell-cycle checkpoints and cancer. Nature, 432:316–323.
9.
LaezzaC., CarusoM.G., GentileT., NotarnicolaM., MalfitanoA.M., DimatolaT., MessaC., GazzerroP., BifulcoM.2009. N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1. Int J Cancer, 124:1322–1329.
10.
LaezzaC., NotarnicolaM., CarusoM.G., MessaC., MacchiaM., BestiniS., MinatoloF., PortellaG., FiorentinoL., StingoS., BifulcoM.2006. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB J, 20:412–418.
11.
MeiselH., GuntherS., MartinD., SchlimmeE.1998. Apoptosis induced by modified ribonucleosides in human cell culture systems. FEBS Lett, 433:265–268.
12.
MittelmanA., EvansJ.T., ChhedaG.B.1975. Cytokinins as chemotherapeutic agents. Ann NY Acad Sci, 255:225–234.
13.
NafisiS., HashemiM., RajabiM., Tajmir-RiahiH.A.2008a. DNA adducts with antioxidant flavonoids apigenin, morin and naringin. DNA Cell Biol, 27:433–442.
14.
NafisiS., ManouchehriF., Tajmir-RiahiH.A., VaravipourM.2008b. Structural features of DNA interaction with caffeine and theophylline. J Mol Struct, 875:392–399.
15.
NorburyC.J., ZhivotovskyB.2004. DNA damage-induced apoptosis. Oncogene, 23:2797–2808.
16.
PalchaudhuriR., HergenrotherP.J.2007. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotech, 18:497–503.
17.
PrudhommeM.2004. Combining DNA damaging agents and Chk1 inhibitors. Curr Med Chem Anti Cancer Agents, 4:435–438.
18.
RajabiM., GorincioiE., SantanielloE.2010. N6-Isopentenyladenosine, an isoprenoid cytokinin endowed with biological activity: cytotoxicity against MDA-MB-231 breast cancer cell line and interaction with bovine serum albumin. Iran J Org Chem, 2:278–284.
19.
RobinsM.J., HallR.H., ThedfordR.1967. N6-(Δ2-Isopentenyl)adenosine, a component of the transfer ribonucleic acid of yeast and of mammalian tissue, methods of isolation, and characterization. Biochemistry, 6:1837–1848.
20.
SkehnP., StorengR., ScudieroD., MonksA., McMohanJ., VisticaD., WarrenJ.T., BokeschH., KenneyS., BoydM.R.1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 82:1107–1112.
21.
SpinolaM., ColomboF., FavellaF.S., DraganiT.A.2007. N6-isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers. Int J Cancer, 120:2744–2748.
22.
SukD., SimpsonC.L., MihichE.1970. Toxicological and antiproliferative effects of N6-(Δ2-Isopentenyl adenosine, a natural component of mammalian transfer RNA. Cancer Res, 30:1429–1436.
23.
Tajmir-RiahiH.A., NeaultJ.F., NaouiM., DiamantoglouS.1995. The effects of HCl on the solution structure of calf thymus DNA: a comparative study of DNA denaturation by proton and metal cations using Fourier transform IR difference spectroscopy. Biopolymers, 35:493–501.
24.
TaoZ.F., LinN.H.2006. Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem, 6:377–388.
25.
VichaiV., KirtikaraK.2006. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc, 1:1112–1116.
26.
WangJ.Y.J.2001. DNA damage and apoptosis. Cell Death Diff, 8:1047–1048.
27.
ZhouB.S., BartekJ.2004. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer, 4:1–10.
